Comparative Pharmacology
Head-to-head clinical analysis: FML FORTE versus OPHTHOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML FORTE versus OPHTHOCORT.
FML FORTE vs OPHTHOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in suppression of inflammation, immune response, and fibroblast proliferation.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
1 drop of 0.25% ophthalmic suspension in the conjunctival sac of the affected eye(s) every 4 hours. In severe conditions, 1 drop every 2 hours initially, taper as response is achieved.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
None Documented
None Documented
Plasma terminal elimination half-life is approximately 3-4 hours (range 2-6 hours) for fluorometholone alcohol; clinical effects may persist longer due to tissue retention.
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Eliminated primarily via hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 60-70%, with about 30-40% excreted in feces via bile.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination